

Novavax Investor Relations

Novavax will present encore safety and immunogenicity data from its COVID-19 vaccine (NVX-CoV2373) trials, as well as encore safety and efficacy data on the Novavax Influenza vaccine candidate at the [Communicable Diseases & Immunisation Conference \(CDIC\) 2022](#) in Sydney, Australia, from June 20 to 22, 2022. Data will be presented during six oral presentations at the conference.

Novavax presentations during CDIC:

Toback, S	Ongoing Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine in the United Kingdom	Oral (encore) Monday, June 20, 2022 1:30 PM - 3:00 PM AEST
Shinde, V	Phase 3 trial of a SARS-CoV-2 Protein Vaccine (NVX-CoV2373) in Adolescents (PREVENT-19)	Oral (encore) Monday, June 20, 2022 1:30 PM - 3:00 PM AEST
Beyhaghi, H	Reported Pregnancies and Associated Outcomes Across the Novavax COVID-19 Vaccine Clinical Program	Oral (encore) Monday, June 20, 2022 3:30 PM - 5:00 PM AEST
Marchese, A	COVID-19 Vaccine Receptivity and Preferences among Vaccine Hesitant Individuals	Oral (encore) Monday, June 20, 2022 3:30 PM - 5:00 PM AEST
Toback, S	The Safety and Efficacy of NVX-CoV2373 Co-administered With Seasonal Influenza Vaccine	Oral (encore) Tuesday, June 21, 2022 1:30 PM - 3:00 PM AEST
Shinde, V	Long-term polyfunctional CD4+ T-cell responses after recombinant hemagglutinin saponin-adjuvanted nanoparticle influenza vaccination	Oral (encore) Tuesday, June 21, 2022 1:30 PM - 3:00 PM AEST

<https://ir.novavax.com/Novavax-to-Showcase-Innovative-Vaccine-Data-at-Communicable-Diseases-Immunisation-Conference-2022>